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Introduction
Worldwide, between 1990 and 2001, mortality rates from
all cancers fell by 17% in those aged 30–69 years and
rose by 0·4% in those aged older than 70 years.1,2 This
deline was lower than the fall in mortality rates from
cardiovascular diseases, which declined by 9% and 14%
in men aged 30–69 years and 70 years or older,
respectively, and of 15% and 11% for women in the
same age groups.1,2
Age-speciﬁc mortality rates for chronic diseases are
driven by changes in exposure to risk factors, and by
availability of screening systems and treatment.
Advances in primary and secondary prevention and in
treatment have been effective in reducing mortality from
cardiovascular diseases over the past few decades, at least
in developed countries.3 Therapeutic interventions have
had less success in reducing deaths from most cancers.
For example, in the USA, age-adjusted death rates for all
cancers combined fell slightly in the 1990s (on average
1·5% per year in men and 0·6% per year in women
between 1992 and 1999).4 The fall in overall cancer
mortality in men was mainly a result of reductions in
mortality from lung, prostate, and colorectal cancers.4 In
women, mortality due to lung cancer increased in the
1990s, but there was a decrease in death rates from breast
and colorectal cancers.4 The fall in lung-cancer mortality
in men was mostly due to lower incidence,4 itself a result
of a reduction in smoking. The causes of decreased
mortality from prostate cancer remain uncertain, since
incidence ﬁgures over time might not be comparable
because of changes in diagnostic techniques and death
certiﬁcation.5 Rates of death from colorectal cancer might
have fallen because of early detection and removal of
precancerous polyps, early detection of tumours, and
improved treatment.6 For breast cancer in women,
increased coverage of mammography screening7 and
successful treatment with multi-agent chemotherapy and
tamoxifen have been effective in reducing mortality.8
Treatment has also been effective for some cancers in
children and young adults—eg, leukaemia and testicular
cancer.9,10 5-year survival rates remain relatively low,
however, for lung, oesophageal, liver, stomach, and
pancreatic cancers (all 25%).9
Although a combination of screening and treatment is
increasingly effective in reducing mortality from some
cancers, limitations in availability of clinical inter-
ventions for other cancers, and in access to and use of
existing technologies, clearly constrain the effects of
treatment on population trends in cancer mortality, even
in developed countries. As such, primary prevention
through lifestyle and environmental interventions might
offer the best option for reducing the large and
increasing burden of cancers worldwide. Policies and
programmes to implement such interventions depend
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Summary
Introduction With respect to reducing mortality, advances in cancer treatment have not been as effective as those for
other chronic diseases; effective screening methods are available for only a few cancers. Primary prevention through
lifestyle and environmental interventions remains the main way to reduce the burden of cancers. In this report, we
estimate mortality from 12 types of cancer attributable to nine risk factors in seven World Bank regions for 2001. 
Methods We analysed data from the Comparative Risk Assessment project and from new sources to assess exposure
to risk factors and relative risk by age, sex, and region. We applied population attributable fractions for individual and
multiple risk factors to site-speciﬁc cancer mortality from WHO. 
Findings Of the 7 million deaths from cancer worldwide in 2001, an estimated 2·43 million (35%) were attributable
to nine potentially modiﬁable risk factors. Of these, 0·76 million deaths were in high-income countries and
1·67 million in low-and-middle-income nations. Among low-and-middle-income regions, Europe and Central Asia
had the highest proportion (39%) of deaths from cancer attributable to the risk factors studied. 1·6 million of the
deaths attributable to these risk factors were in men and 0·83 million in women. Smoking, alcohol use, and low fruit
and vegetable intake were the leading risk factors for death from cancer worldwide and in low-and-middle-income
countries. In high-income countries, smoking, alcohol use, and overweight and obesity were the most important
causes of cancer. Sexual transmission of human papilloma virus is a leading risk factor for cervical cancer in women
in low-and-middle-income countries. 
Interpretation Reduction of exposure to key behavioural and environmental risk factors would prevent a substantial
proportion of deaths from cancer. 
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on reliable and comparable analyses of the effect of risk
factors for cancer at the population level. 
Several reports have quantiﬁed the effects of risk
factors on cancer incidence and mortality, as
summarised in the World Cancer Report.11 Most of these
studies, however, are restricted to one risk factor, one
site of cancer, or one population.12–18 Pisani and
colleagues19 estimated the worldwide proportion of
cancer incidence attributable to selected infectious
agents to be about 16%. Parkin and colleagues20
presented attributable fractions for several risk factor-
cancer site combinations based on a review of published
studies. Our aim was to estimate the worldwide and
regional mortality from site-speciﬁc cancers attributable
to speciﬁc risk factors, individually and jointly. 
Methods 
Risk factors assessed 
We used systematic reviews and meta-analyses of the
evidence on risk factor exposure and relative risk from
the Comparative Risk Assessment project21,22 and data
from new sources to quantify the effect of a group of risk
factors on cancer mortality (table 1).23–31 We selected the
risk factors on the basis of the following criteria: likely to
be a leading cause of worldwide or regional disease
burden; not too speciﬁc (eg, speciﬁc types of fruits and
vegetables) or too broad (eg, diet as a whole) for
comparable deﬁnition and quantiﬁcation of exposure in
different populations; high likelihood of causality;
reasonably complete data on population exposure and
risk levels, or appropriate methods for extrapolation
when necessary; and potentially modiﬁable. 
Procedures 
For every risk factor, an expert working group undertook
comprehensive and systematic reviews of published
studies and other sources (eg, government reports,
international databases) to obtain data on the risk-factor
exposure and relative risk (RR). The groups also obtained
primary data, and undertook reanalyses of original data
Exposure variable Theoretical-minimum-risk Cancer sites affected (age groups assessed)†
exposure distribution
Diet and physical inactivity
Overweight and BMI (kg/m2) 21 SD 1 kg/m2 Corpus uteri cancer, colorectal cancers (30 years), post-
obesity (high BMI)23 menopausal breast cancer (45 years), gallbladder cancer,
kidney cancer
Low fruit and vegetable Fruit and vegetable intake per day 600 SD 50 g intake per Colorectal cancer, stomach cancer, lung cancer, 
intake24 day for adults oesophageal cancer (15 years)
Physical inactivity25 Three categories: inactive, insufﬁciently active (2·5 h per week of 2·5 h per week of Breast cancer, colorectal cancer (15 years), prostate cancer
moderate-intensity activity, or 4000 KJ per week), and sufﬁciently moderate-intensity 
active. Activity in spare time, work, and transport considered activity or equivalent 
(400 KJ per week)
Addictive substances
Smoking26 Current levels of smoking impact ratio (indirect indicator of No smoking Lung cancer, mouth and oropharynx cancer, oesophageal 
accumulated smoking risk based on excess lung-cancer mortality) cancer, stomach cancer, liver cancer, pancreatic cancer,
cervix uteri cancer, bladder cancer, leukaemia (30 years)
Alcohol use27 Current alcohol consumption volumes and patterns No alcohol use‡ Liver cancer, mouth and oropharynx cancer, breast cancer,
oesophageal cancer, selected other cancers (15 years)
Sexual and reproductive health
Unsafe sex28 Sex with an infected partner without any measures to prevent No unsafe sex Cervix uteri cancer (all ages)§
infection
Environmental risks
Urban air pollution29 Estimated yearly average particulate matter concentration for 7·5 g/m3 for PM2·5 Lung cancer (30 years)
particles with aerodynamic diameters 2·5 microns or 10 microns 15 g/m3 for PM10
(PM2·5 or PM10)
Indoor smoke from household Household use of solid fuels No household solid fuel use Lung cancer (coal) (30 years)
use of solid fuels30 with limited ventilation
Other selected risks
Contaminated injections Exposure to 1 contaminated injection (contamination refers to No contaminated injections Liver cancer (all ages)
in health-care settings31 potential transmission of hepatitis B virus and hepatitis C virus)
*New exposure data and epidemiological evidence on disease outcomes and relative risks used when new epidemiological analyses allowed improvements compared with original analyses of Comparative Risk Assessment
project—eg, relative risks for site-speciﬁc cancers as a result of smoking with better adjustment for potential confounders and new exposure data sources for overweight and obesity. †Italics=outcomes likely to be causal but not
quantiﬁed because of insufﬁcient evidence on prevalence or hazard size. Corresponding ICD 9 3-digit codes: bladder cancer 188; breast cancer 174; cervix uteri cancer 180; colorectal cancers 153–154; corpus uteri cancer 
179, 182; leukaemia 204–208; liver cancer 155; mouth and oropharynx cancer 140–149; oesophageal cancer 150; pancreatic cancer 157; stomach cancer 151; trachea, bronchus, and lung cancers 162; selected other cancers
210–239. Total deaths from cancer are from WHO. Methods used by WHO32,33 are based on a combination of vital statistics for countries with complete vital registration and medical certiﬁcation of deaths, and on a combination
of demographic techniques and information from cancer registries for countries with incomplete vital statistics, with sample registration or surveillance systems, or without vital registration. ‡Alcohol has beneﬁts as well as
harms for different diseases, also depending on patterns of alcohol consumption. A theoretical minimum of zero was chosen for alcohol use because, despite beneﬁts for speciﬁc diseases (cardiovascular) in some populations
global and regional burden of disease due to alcohol use was dominated by its effects on neuropsychological diseases and injuries, which are considerably larger than beneﬁts to vascular diseases. Furthermore, no beneﬁts for
neoplastic disease have been noted from alcohol. §A proportion of HPV infections that lead to cervix uteri cancer are transmitted through routes other than sexual contact. PAF for unsafe sex, as deﬁned in the comparative risk
assessment project,28 measures current population-level cervix cancer mortality that would be reduced, had there never been any sexual transmission of infection—ie, the consequences of past and current exposure, as we do for
accumulated hazards of smoking. By considering health consequences of past and current exposure, nearly all of sexually transmitted diseases are attributable to unsafe sex because, in the absence of sexual transmission in the
past, current infections transmitted through other forms of contact would not occur if infected hosts acquired their infection sexually (and so on in the sequence of past infected hosts).
Table 1: Cancer risk factors, exposure variables, theoretical-minimum-risk exposure distributions, disease outcomes*
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sources and meta-analyses of epidemiological studies.
The details of data sources and analyses for each risk
factor are provided in references cited in table 1. All
sources cited in table 1 have been peer-reviewed by
external reviewers. The expert working groups presented
exposure and RRs separately for men and women, for
eight age groups (0–4, 5–14, 15–29, 30–44, 45–59, 60–69,
70–79, and 80 years), and for the 14 epidemiological
subregions used in the Global Burden of Disease study;22
converted to World Bank regions here because they
correspond better to geographically well known regions
of the world (webtables 1 and 2). 
Statistical analysis
To estimate the population attributable fractions (PAF)
for individual risk factors, we used the equation shown
in the panel, or its discreet version for risk factors with
categorical exposure data. For every risk factor and
cancer site, we used PAF to estimate the proportional
reduction in site-speciﬁc cancer death that would arise if
exposure to the risk factor were reduced to the
counterfactual distribution. The alternative (counter-
factual) scenario used in this study is deﬁned as the
exposure distribution that would result in the lowest
population risk, referred to as the theoretical-minimum-
risk exposure distribution (table 1). This method
provides a quantitative assessment of the potential
reduction in cancer burden in a consistent and
comparable way across risk factors. The theoretical-
minimum-risk exposure distribution is zero for risk
factors for which zero exposure could be deﬁned, and
would indicate minimum risk (eg, the whole population
being lifelong non-smokers). For some risk factors, zero
exposure is an inappropriate choice, either because it is
physiologically impossible (eg, body-mass index [BMI])
or because there are physical lower limits to exposure
reduction (eg, concentration of ambient particulate
matter). For these risk factors, we used the lowest levels
noted in speciﬁc populations from epidemiological
studies. For risk factors with protective effects (ie, fruit
and vegetable intake, physical activity) we chose a
counterfactual exposure distribution based on a
combination of levels observed in high-intake
populations  and the level up to which health beneﬁts
might accrue. 
Because most cancers are caused by multiple risk
factors, PAFs for individual risk factors for the same
cancer site overlap and can add to more than 100%. For
example, more than 70% of Chinese households rely on
solid fuels (coal and biomass) for cooking and heating,30
and more than 60% of Chinese men smoke. Since
smoking and coal smoke magnify one another’s hazards
for lung cancer,13 some deaths from lung cancer can be
prevented by removal of smoking or of exposure to
indoor smoke from coal. Such cases would be attributed
to both risk factors. Multicausality also means that a
range of interventions can be used for disease
prevention, with the speciﬁc mix being affected by factors
such as cost, technology availability, infrastructure, and
preferences. We therefore also estimated the PAFs for
multiple risk factors, as described in detail elsewhere.34
We calculated all individual and joint PAFs by sex and
by eight age groups. For every World Bank region, age,
sex, and cancer site, we multiplied the PAF by total
regional site-speciﬁc cancer mortality for the year 2001
(from WHO databases) to calculate deaths from site-
speciﬁc cancer attributable to the risk factor or group of
risk factors. Attributable deaths were aggregated into
three age groups for presentation (age-speciﬁc results
available from the corresponding author).
Role of the funding source
The sponsor of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had full
access to all the data in the study and had ﬁnal
responsibility for the decision to submit for publication.
Results 
Table 2 shows the estimated individual and joint
contributions of the selected risk factors to mortality for
each cancer site, for the world, and separately for low-
and-middle-income, and high-income countries. The
joint effects are further divided by region for low-and-
middle-income countries in ﬁgure 1, by sex and by
income in ﬁgure 2, and by age in table 3. Of the 7 million
global deaths from cancer in 2001, an estimated
2·43 million (35%) were attributable to the joint effect of
the nine risk factors listed in table 1.
Cancers with the largest proportions (60%) attrib-
utable to these risks were cervix uteri cancer, lung
cancer, and oesphagus cancer. The main risk factors for
these cancers included sexual transmission of HPV
leading to persistent infection with oncogenic viruses,
smoking, alcohol use, and low fruit and vegetable intake.
Cancers with the smallest joint PAFs (colorectal cancers
[13%] and leukaemia [9%]) were those with a large
number of risks with heterogeneous and unmeasured
exposure patterns across populations, possibly including
major genetic susceptibilities.
More than a third (37%) of all risk-factor attributable
deaths (908 000 deaths) were from lung cancer,
Panel: Continuous PAF formula
=risk factor exposure level 
P()=population distribution of exposure
P()=counterfactual distribution of exposure
RR()=relative risk of mortality from site-speciﬁc cancer at exposure level 
m=maximum exposure level 
 RR()P()d–  RR()P()d
PAF=  
=0 =0
m
 RR()P()d
=0
m
m
See Lancet Online
for webtables 1 and 2
For details of data sources and
analyses for each risk factor, 
see http://www.who.int/
publications/cra/en/index.html
Articles
www.thelancet.com Vol 366   November 19, 2005  1787
Total deaths PAF (%) and number of attributable cancer PAF due to  
deaths (thousands) for individual risk factors joint hazards
of risk factors
Worldwide
Mouth and oropharynx cancers 311 633 Alcohol use (16%, 51), smoking (42%, 131) 52%
Oesophageal cancer 437 511 Alcohol use (26%, 116), smoking (42%, 184), low fruit and vegetable intake (18%, 80) 62%
Stomach cancer 841 693 Smoking (13%, 111), low fruit and vegetable intake (18%, 147) 28%
Colon and rectum cancers 613 740 Overweight and obesity (11%, 69), physical inactivity (15%, 90), low fruit and vegetable intake (2%, 12) 13%
Liver cancer 606 441 Smoking (14%, 85), alcohol use (25%, 150), contaminated injections in health-care settings (18%, 111) 47%
Pancreatic cancer 226 981 Smoking (22%, 50) 22%
Trachea, bronchus, and lung cancers 1 226 574 Smoking (70%, 856), low fruit and vegetable intake (11%, 135), indoor smoke from household use of solid fuels (1%, 16), 74%
urban air pollution (5%, 64)
Breast cancer 472 424 Alcohol use (5%, 26), overweight and obesity (9%, 43), physical inactivity (10%, 45) 21%
Cervix uteri cancer 234 728 Smoking (2%, 6), unsafe sex (100%, 235) 100%
Corpus uteri cancer 70 881 Overweight and obesity (40%, 28) 40%
Bladder cancer 175 318 Smoking (28%, 48) 28%
Leukaemia 263 169 Smoking (9%, 23) 9%
Selected other cancers 145 802 Alcohol use (6%, 8) 6%
All other cancers 1 391 507 None of selected risk factors 0%
All cancers 7 018 402 Alcohol use (5%, 351), smoking (21%, 1493), low fruit and vegetable intake (5%, 374), indoor smoke from household 35%
use of solid fuels (0·5%, 16), urban air pollution (1%, 64), overweight and obesity (2%, 139), physical inactivity (2%, 135), 
contaminated injections in health-care settings (2%, 111), unsafe sex (3%, 235)
Low-and-middle-income countries
Mouth and oropharynx cancers 271 074 Alcohol use (14%, 38), smoking (37%, 100) 48%
Oesophageal cancer 379 760 Alcohol use (24%, 92) smoking (37%, 141), low fruit and vegetable intake (19%, 73) 58%
Stomach cancer 695 426 Smoking (11%, 74), low fruit and vegetable intake (19%, 130) 27%
Colon and rectum cancers 356 949 Overweight and obesity (9%, 32), physical inactivity (15%, 54), low fruit and vegetable intake (2%, 9) 11%
Liver cancer 504 407 Smoking (11%, 56), alcohol use (23%, 117), contaminated injections in health-care settings (21%, 108) 45%
Pancreatic cancer 116 827 Smoking (15%, 18) 15%
Trachea, bronchus, and lung cancers 770 938 Smoking (60%, 466), low fruit and vegetable intake (13%, 98), indoor smoke from household use of solid fuels (2%, 16), 66%
urban air pollution (7%, 52)
Breast cancer 317 195 Alcohol use (4%, 12), overweight and obesity (7%, 23), physical inactivity (10%, 30) 18%
Cervix uteri cancer 218 064 Smoking (2%, 4), unsafe sex (100%, 218) 100%
Corpus uteri cancer 43 926 Overweight and obesity (37%, 16) 37%
Bladder cancer 116 682 Smoking (21%, 24) 21%
Leukaemia 190 059 Smoking (6%, 11) 6%
Selected other cancers 88 706 Alcohol use (4%, 3) 4%
All other cancers 882 001 None of selected risk factors 0%
All cancers 4 952 014 Alcohol use (5%, 262), smoking (18%, 896), low fruit and vegetable intake (6%, 311), indoor smoke from household 34%
use of solid fuels (0·5%, 16), urban air pollution (1%, 52), overweight and obesity (1%, 71), physical inactivity (2%, 84), 
contaminated injections in health-care settings (2%, 108), unsafe sex (4%, 218)
High-income countries
Mouth and oropharynx cancers 40 559 Alcohol use (33%, 14), smoking (71%, 29) 80%
Oesophageal cancer 57 752 Alcohol use (41%, 24), smoking (71%, 41), low fruit and vegetable intake (12%, 7) 85%
Stomach cancer 146 267 Smoking (25%, 36), low fruit and vegetable intake (12%, 17) 34%
Colon and rectum cancers 256 791 Overweight and obesity (14%, 37), physical inactivity (14%, 36), low fruit and vegetable intake (1%, 3) 15%
Liver cancer 102 033 Smoking (29%, 29), alcohol use (32%, 33), contaminated injections in health-care settings (3%, 3) 52%
Pancreatic cancer 110 154 Smoking (30%, 33) 30%
Trachea, bronchus, and lung cancers 455 636 Smoking (86%, 391), low fruit and vegetable intake (8%, 36), indoor smoke from household use of solid fuels (0%), 87%
urban air pollution (3%, 12)
Breast cancer 155 230 Alcohol use (9%, 14), overweight and obesity (13%, 20), physical inactivity (9%, 15) 27%
Cervix uteri cancer 16 663 Smoking (11%, 2), unsafe sex (100%, 17) 100%
Corpus uteri cancer 26 955 Overweight and obesity (43%, 12) 43%
Bladder cancer 58 636 Smoking (41%, 24) 41%
Leukaemia 73 110 Smoking (17%, 12) 17%
Selected other cancers 57 095 Alcohol use (8%, 5) 8%
All other cancers 509 507 None of selected risk factors 0%
All cancers 2 066 388 Alcohol use (4%, 88), smoking (29%, 596), low fruit and vegetable intake (3%, 64), indoor smoke from household use of 37%
solid fuels (0%, 0), urban air pollution (1%, 12), overweight and obesity (3%, 69), physical inactivity (2%, 51), contaminated 
injections in health-care settings (0·5%, 3), unsafe sex (1%, 17)
Results for individual regions available from corresponding author.
Table 2: Individual and joint contributions of risk factors in table 1 to mortality from site-speciﬁc cancers
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12% from liver cancer (283 000 deaths), and 11% from
oesophageal cancer (271 000 deaths), reﬂecting the
combinations of relatively large joint PAFs applied to
large numbers of deaths from these cancers (table 2). All
three cancers have 5-year survival rates of less than 25%.
Leukaemia (23 000) and corpus uteri cancer (28 000) had
the smallest number of attributable deaths (3% of deaths
from leukaemia were attributed to occupational
exposures,35 not re-analysed here because of difﬁculties
in converting exposure to new regions).
Despite having only 15% of the world’s population
(21% of the population aged 30 years), high-income
countries accounted for 29% of the 7 million deaths
from cancer worldwide and 31% of the 2·43 million that
were attributable to the selected risks in table 1; the
remaining 1·67 million attributable deaths occurred in
low-and-middle-income countries. Except for cervix uteri
cancer, joint PAFs were greater in high-income
countries than in low-and-middle-income countries for
all cancer sites. This ﬁnding is mostly a result of higher
and longer population exposure to smoking and alcohol
use, and is particularly evident for lung, mouth and
oropharynx, and oesophageal cancers, especially in men.
The joint PAFs for all cancers combined, however, were
similar for both groups of countries (37% in high-
income and 34% in low-and-middle-income regions).
The smaller difference in all-site PAF than in PAFs for
site-speciﬁc cancers arises because the contribution of
site-speciﬁc cancers to total cancer mortality varies (eg,
stomach and liver cancers caused 695 000 [14% of all
deaths from cancer] and 504 000 [10% of all deaths from
cancer] deaths, respectively, in low-and-middle-income
countries, and 146 000 [7% of all deaths from cancer]
and 102 000 [5% of all deaths from cancer] deaths in
high-income countries). Furthermore, those cancer sites
that were not affected by risk factors in table 1 accounted
for 18% of all deaths from cancer in low-and-middle-
income countries, but 25% in high-income nations.
Lung, liver, and oesophageal cancers had the largest
number of attributable deaths in low-and-middle-
income countries (512 000, 229 000, and 222 000,
respectively). In high-income countries, lung cancer
alone constituted 52% of all risk-factor attributable
deaths from cancer (396 000 deaths); other cancers
accounted for 7% or less, indicating the fairly successful
preventive interventions for some of these cancers (eg,
reduction in liver cancer as a result of reduced exposure
to infectious agents) and the disproportionate rise in
lung cancer mortality in many high-income countries
where smoking prevalence remains high.
In low-and-middle-income countries, the joint PAF for
all cancer sites combined was largest in Europe and
Central Asia (ECA; 39%) and smallest in the Sub-
Saharan Africa (SSA; 24%) and Middle East and North
Africa (MENA; 24%) regions. For men, ECA had the
largest joint PAF (50%) and SSA the smallest (19%),
being strongly affected by the role of smoking, alcohol
Tr
ac
he
a, 
br
on
ch
us
, a
nd
 lu
ng
 ca
nc
ers
St
om
ac
h c
an
ce
r
Liv
er 
ca
nc
er
Oe
so
ph
ag
ea
l c
an
ce
r 
Co
lon
 an
d r
ec
tu
m
 ca
nc
ers
Br
ea
st 
ca
nc
er
Mo
ut
h a
nd
 or
op
ha
ryn
x c
an
ce
rs
Ce
rvi
x u
te
ri c
an
ce
r
Le
uk
ae
m
ia
Pa
nc
rea
tic
 ca
nc
er
Bla
dd
er 
ca
nc
er
Co
rp
us
 ut
eri
 ca
nc
er
East Asia and Pacific
Europe and Central Asia
Latin America and Caribbean
Middle East and north Africa
South Asia
Sub-Saharan Africa
600 000
800 000
400 000
200 000
0
N
um
be
r o
f d
ea
th
s
Figure 1: Deaths from site-speciﬁc cancers attributable to selected risk factors in low-and-middle-income
countries, by region
For every cancer site, solid blocks of colour represent deaths not attributable to risks assessed and broken blocks of
colour represent deaths attributable to selected risk factors in table 1.
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use, and overweight and obesity; for women, SSA had the
highest PAF (29%) and MENA the smallest (19%). The
main driver of the high PAF for women in SSA was the
large number of deaths from cervix uteri cancer, which is
in turn affected by limited access to cervical screening
above and beyond sexual transmission of HPV. 
The largest number of deaths attributable to the
selected risks in table 1 in the low-and-middle-income
countries was in EAP (746 000; 45% of all attributable
deaths from cancer in low-and-middle-income
countries), ECA (324 000; 19%) and South Asia region
(SAR: 322 000; 19%). In all three regions, the total
number of deaths from cancer is large, mostly because
of the large population size in EAP and SAR. The
population of ECA is smaller, but the total number of
deaths from cancer is relatively high and larger
proportions are attributable to the individual and joint
hazards of these risk factors, especially smoking. MENA
and SSA had the smallest number of deaths from cancer
attributable to the risk factors considered here (40 000
and 97 000, respectively), because of both the smaller
total number of deaths from cancer and the lower PAFs
attributable to these risks.
Smoking alone is estimated to have caused 21% of
deaths from cancer worldwide. Alcohol use and low fruit
and vegetable intake caused another 5% each. Smoking
was responsible for a higher fraction of deaths from
cancer in high-income countries (29%) than in low-and-
middle-income regions (18%), because of the shorter
history of smoking and lower prevalence among women.
However, the number of smoking-attributable deaths
from cancer was larger in the low-and-middle-income
countries (896 000 vs 596 000) because of the larger total
number of deaths from cancer. All-cancer-site PAF for
alcohol use was almost equal in the two groups of
countries because of large numbers of alcohol-
attributable deaths in ECA and EAP. In EAP, liver and
oesophagus were the cancer sites with the largest
number of deaths attributable to alcohol use. In addition
to smoking and alcohol use, some risks with well
established interventions also caused considerable
excess cancer mortality in low-and-middle-income
regions: contaminated injections in health-care settings
caused 108 000 deaths in the six regions, 91 000 of them
in EAP; the cancer hazards of indoor smoke from solid
fuels were restricted to EAP and SAR, where coal is
used, causing 16 000 deaths from lung cancer (other
regions use biomass fuels for which lung cancer hazards
have not yet been established30). The proportion of all-
site-cancer deaths attributable to overweight or obesity
and physical inactivity was highest in ECA, indicating
the relatively high population exposure to these lifestyle
related risk factors, which coexist with the risk from
smoking and alcohol use.
The risk factors studied caused about twice as many
deaths from cancer in men as in women (1·6 vs
0·83 million); the fraction of deaths from cancer
attributable to these risks was 41% for men versus 27%
for women. Lung cancer contributed the most to the
risk-factor attributable deaths in men (45% of all
attributable deaths) and cervix uteri cancer in women
(28% of all attributable deaths). Smoking and alcohol
use played an important part in male–female differences
in PAFs and attributable deaths. Excluding cervix,
corpus uteri, and breast cancers, and their speciﬁc risk
factors, which almost exclusively affect women, the total
number of deaths from major cancers (lung, stomach,
and liver) as well as the number attributable to the major
risks, was higher in men than women (ﬁgure 2). This
pattern did not follow for colorectal cancer, where
smoking and alcohol use have no established role. The
largest male–female difference in PAFs was for mouth
or oropharynx cancer, which is strongly affected by
alcohol use and smoking (66% for men vs 23% for
women). Mouth or oropharynx cancer also had the
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Figure 2: Worldwide deaths from site-speciﬁc cancers attributable to selected risk factors by sex
For every cancer site, solid blocks of colour represent deaths not attributable to risks assessed and broken blocks of
colour represent deaths attributable to selected risk factors in table 1.
Articles
1790 www.thelancet.com Vol 366   November 19, 2005 
largest sex difference in low-and-middle-income
countries (63% for men vs 17% for women); in high-
income countries, liver cancer had the largest sex
difference in PAFs (59% for men vs 37% for women). 
Except for lung cancer in high-income countries, joint
PAFs were largest for those aged 30–69 years. This
ﬁnding is in part the result of the cohort effects of
exposure to smoking and alcohol use. More than half of
all deaths from cancer were between ages 30 years and 69
years (table 3). The largest number of attributable deaths
for all cancer sites, except bladder, was also noted in this
age group, pointing to the potential large gains in life
expectancy that could be achieved by reducing exposure
to these risk factors. Leukaemia claimed the largest total
number of deaths from cancer in the youngest age group
(30 years). None of the leukaemia deaths in these ages
were attributed to the risk factors we assessed because
most epidemiological studies only estimate hazards after
the age of 30 years. Although the total number of deaths
from cancer in those younger than age 30 years was
generally low, the low-and-middle-income countries had
noticeably larger numbers of deaths and higher PAFs in
this age group (largely due to the large number of deaths
from liver cancer attributable to contaminated
injections), indicating the success of the cancer control
programmes for young people in high-income nations.
Discussion
More than one in every three of the 7 million deaths
from cancer worldwide is caused by nine potentially
Age Total attributable 
deaths
0–29 years 30–69 years 70 years
World
Mouth and oropharynx cancers 6 (15%, 1) 204 (58%, 118) 101 (44%, 44) 163
Oesophageal cancer 2 (38%, 0·8) 264 (66%, 175) 172 (55%, 95) 271
Stomach cancer 9 (21%, 2) 455 (32%, 145) 378 (24%, 92) 240
Colon and rectum cancers 6 (3%, 0·2) 282 (14%, 40) 326 (12%, 40) 79
Liver cancer 16 (36%, 6) 394 (49%, 195) 196 (42%, 82) 283
Pancreatic cancer 0·7 (0%, 0) 111 (23%, 25) 115 (22%, 25) 50
Trachea, bronchus, and lung cancers 5 (11%, 0·5) 684 (74%, 503) 537 (75%, 405) 908
Breast cancer 2 (0%, 0) 305 (20%, 61) 165 (22%, 37) 98
Cervix uteri cancer 11 (100%, 11) 156 (100%, 156) 67 (100%, 67) 235
Corpus uteri cancer 0·4 (0%, 0) 35 (43%, 15) 36 (37%, 13) 28
Bladder cancer 1 (0%, 0) 67 (29%, 19) 106 (27%, 29) 48
Leukaemia 75 (0%, 0) 107 (12%, 13) 81 (12%, 10) 23
All cancers 222 (10%, 21) 3783 (39%, 1467) 3013 (31%, 939) 2427
Low-and-middle-income countries
Mouth and oropharynx cancers 6 (14%, 0·9) 180 (55%, 98) 85 (37%, 32) 131
Oesophageal cancer 2 (38%, 0·8) 235 (64%, 150) 143 (50%, 71) 222
Stomach cancer 8 (21%, 2) 399 (31%, 124) 288 (22%, 64) 191
Colon and rectum cancers 6 (3%, 0·2) 193 (12%, 24) 158 (10%, 16) 40
Liver cancer 16 (36%, 6) 346 (48%, 167) 142 (40%, 56) 229
Pancreatic cancer 0·6 (0%, 0) 68 (18%, 12) 48 (11%, 5) 18
Trachea, bronchus, and lung cancers 4 (11%, 0·5) 482 (68%, 329) 284 (64%, 183) 512
Breast cancer 2 (0%, 0) 227 (18%, 40) 89 (18%, 16) 56
Cervix uteri cancer 11 (100%, 11) 146 (100%, 146) 61 (100%, 61) 218
Corpus uteri cancer 0·4 (0%, 0) 25 (41%, 10) 19 (34%, 6) 16
Bladder cancer 1 (0%, 0) 53 (25%, 13) 62 (18%, 11) 24
Leukaemia 70 (0%, 0) 81 (10%, 8) 39 (7%, 3) 11
All cancers 206 (10%, 20) 2946 (38%, 1123) 1800 (29%, 524) 1668
High-income countries
Mouth and oropharynx cancers 0·2 (34%, 0) 24 (82%, 20) 16 (78%, 13) 32
Oesophageal cancer 0·1 (55%, 0) 29 (87%, 25) 29 (83%, 24) 49
Stomach cancer 0·5 (19%, 0) 56 (37%, 21) 90 (31%, 28) 49
Colon and rectum cancers 0·5 (2%, 0) 88 (18%, 16) 168 (14%, 24) 40
Liver cancer 0·4 (33%, 0·1) 48 (57%, 28) 54 (48%, 26) 53
Pancreatic cancer 0·1 (0%, 0) 43 (30%, 13) 67 (30%, 20) 33
Trachea, bronchus, and lung cancers 0·3 (11%, 0) 202 (86%, 174) 253 (88%, 222) 396
Breast cancer 0·3 (0%, 0) 79 (27%, 22) 76 (27%, 21) 42
Cervix uteri cancer 0·2 (100%, 0·2) 10 (100%, 10) 6 (100%, 6) 17
Corpus uteri cancer 0 (0%, 0) 10 (48%, 5) 17 (41%, 7) 12
Bladder cancer 0 (0%, 0) 14 (43%, 6) 44 (40%, 18) 24
Leukaemia 4 (0%, 0) 26 (19%, 5) 43 (17%, 7) 12
All cancers 16 (4%, 0·6) 837 (41%, 343) 1212 (34%, 415) 759
Numbers in brackets show PAF (%) and number of attributable deaths (thousands) for the joint effects of risk factors in table 1. Only cancer sites affected by risk factors in table 1 are
shown.
Table 3: Total cancer deaths (thousands) by age and cancer site
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modiﬁable risk factors, with smoking and alcohol use
having particularly important roles in both high-income
and low-and-middle-income countries. Sexual trans-
mission of HPV, leading to persistent infection with
oncogenic types of virus, as a risk factor for cervix uteri
cancer is a major risk factor for women, especially in the
poorest regions (SSA and SAR) where access to
screening for cervical cancer is limited. Other potentially
modiﬁable risk factors, which have not been assessed
here, might increase this proportion substantially for
some cancer sites. Our estimate of the proportion of
deaths attributable worldwide to the nine risk factors we
studied is about half of what Doll and Peto estimated18 by
comparing age-standardised incidence rates from the
USA from 1978 with the lowest reliably observed
incidence rates in other populations. Because Doll and
Peto18 used comparison of incidence rates, their
estimates include differences in exposure to all known
and unknown risk factors. Furthermore, their estimates
applied to the USA only. Therefore the estimates of Doll
and Peto are not directly comparable to ours.
Some important cancers (eg, prostate, kidney,
melanoma, and lymphomas) were not attributable to any
of the risks we assessed. These cancers are those with
multiple conﬁrmed or suspected environmental and
behavioural risks, with heterogeneous exposure patterns
that make exposure and hazard quantiﬁcation difﬁcult.
Furthermore, we did not assess some fairly well known
risk factors, such as occupational exposures, which are
responsible for 102 000 deaths from cancer worldwide;35
Helicobacter pylori exposure in food; and exposure to
ultraviolet light and environmental tobacco smoke. We
excluded these factors for the main part because of the
limitations of deriving detailed exposure estimates from
existing data (eg, extent of exposure to environmental
tobacco smoke depends on public smoking regulation,
exposure to ultraviolet light depends on the time spent
outdoors and use of protection, and exposure to H pylori
depends on methods of food preservation). 
There are several sources of uncertainty for exposure
and relative risks in our estimates, especially those that
involve extrapolation of exposure and hazard from one
population to another. These are described in more
detail in the descriptions of the data sources for each risk
factor.21, 23–31 The sources of uncertainty in methods and
assumptions for estimating joint PAFs, and the
sensitivity of results to these assumptions, have also
been described elsewhere.34 In addition to uncertainty in
individual and joint PAFs, there is uncertainty in total
site-speciﬁc cancer mortality to which the PAFs are
applied.32,33 75 countries have reasonably complete vital
registration and medical certiﬁcation of deaths.32,33
Another 51 countries have incomplete vital statistics, or
use sample registration or surveillance systems. The
remaining 65 countries, mostly in sub-Saharan Africa,
have no reliable data on adult mortality. WHO uses
standard demographic techniques36 to estimate all-cause
death rates by age for these populations. Cause-of-death
models are then used to estimate the total number of
deaths from cancer for countries with poor data. The
distribution of deaths from cancer by site is based on
regional incidence or mortality patterns from cancer
registries, which report to the International Agency for
Research on Cancer (IARC),37 or on cancer survival
models when such data are unavailable. IARC also
provides estimates of cancer mortality by site for most
WHO member states. The implications of these
different approaches have been discussed previously,
including an assessment of their comparability.32,33 The
net result is that the WHO estimates of global cancer
mortality are 11% higher than those of IARC, with larger
differences for SSA, SAR, and MENA. 
Decades of biodmedical research in developed nations
have resulted in many effective interventions that affect
cancer incidence and mortality. Examples include
hepatitis B vaccine for liver cancer, screening methods
for cervical cancer,38,39 faecal occult blood test for colo-
rectal cancer,40–42 mammography for breast cancer,43,44
and surgical prevention for those at high risk of
colorectal cancers.45 Undoubtedly, increased coverage of
the above technologies, especially those that involve
early detection, would help reduce further the burden of
cancers. There has, however, been less success with
respect to other cancers: sputum cytology and chest 
radiographs for lung cancer have not been promising,
and multiple chest radiographs might even be harmful;46
and vaccines for H pylori and HPV are still under
investigation.47,48 The efﬁcacy of chemotherapy and
radiotherapy varies from cancer to cancer and depends
on multiple technical and biological factors, such as
stage of cancer. 
Summarising the changes made in cancer therapy
over the past three decades, Sporn49 states that the
obsession with curing advanced disease has prevented
progress in the war on cancer. Furthermore, preventive,
screening, and treatment interventions will only affect
population statistics if they are accessible and used,
factors that are highly dependent on cost and health-
system characteristics. These factors limit large-scale
application of these interventions in resource-poor
settings. These limitations further reinforce the
importance of our results for policies and programmes
that modify behavioural and environmental factors to
reduce the burden of cancers.
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